Form 8-K
8-K — NU SKIN ENTERPRISES, INC.
Accession: 0001140361-26-019586
Filed: 2026-05-07
Period: 2026-05-07
CIK: 0001021561
SIC: 5122 (WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES)
Item: Results of Operations and Financial Condition
Item: Financial Statements and Exhibits
Documents
8-K — ef20072663_8k.htm (Primary)
EX-99.1 — PRESS RELEASE DATED MAY 7, 2026 (ef20072663_ex99-1.htm)
GRAPHIC (image01.jpg)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K — FORM 8-K
8-K (Primary)
Filename: ef20072663_8k.htm · Sequence: 1
false000102156100010215612026-05-072026-05-07
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
May 7, 2026
Date of Report (Date of earliest event reported)
NU SKIN ENTERPRISES, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-12421
87-0565309
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification Number)
75 West Center Street
Provo, Utah 84601
(Address of principal executive offices and zip code)
(801) 345-1000
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Class A Common Stock, $.001 par value
NUS
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02
Results of Operations and Financial Condition.
On May 7, 2026, Nu Skin Enterprises, Inc. (the “Company”) issued a press release announcing its financial results for the three-month period ended March 31, 2026, and
certain other information. A copy of the press release is attached as Exhibit 99.1 to this report.
The information furnished pursuant to this Item 2.02 and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits.
99.1
Nu Skin Enterprises’ press release dated May 7, 2026, regarding financial results for the three-month period ended March 31, 2026.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
NU SKIN ENTERPRISES, INC.
(Registrant)
/s/ Chelsea K. Lantz
Chelsea K. Lantz
Chief Financial Officer
Date: May 7, 2026
EX-99.1 — PRESS RELEASE DATED MAY 7, 2026
EX-99.1
Filename: ef20072663_ex99-1.htm · Sequence: 2
Exhibit 99.1
FOR IMMEDIATE RELEASE
Nu Skin Enterprises Reports First Quarter Results
PROVO, Utah — May 7, 2026 — Nu Skin Enterprises Inc.
(NYSE: NUS) today announced first quarter revenue results within its guidance range.
Executive Summary
Q1 2026 vs. Prior-year Quarter
Revenue
$320.6 million; (12.0)%
• +1.1% FX impact or
$3.9 million
Earnings Per Share (EPS)
$0.04 or $0.14 excluding certain charges compared to $2.14 or $0.23 excluding one-time gain from Mavely sale and other charges
Customers
669,535; (14)%
Paid Affiliates
120,850; (8)%
Sales Leaders
26,915; (13)%
“We delivered first quarter revenue in line with our expectations and made further progress in our strategic priorities while operating in a volatile environment,” said
Ryan Napierski, Nu Skin president and CEO. “As we move through 2026, we are focused on empowering our sales leaders to scale our intelligent wellness platform with our latest innovation, Prysm iO™, ahead of our full consumer rollout in the second
half. We also continue to invest in laying the groundwork to expand our presence in emerging markets, including the formal launch of India anticipated in late 2026, while continuing to improve our operational discipline to return value to
shareholders.
“We are encouraged by early signs of improving paid affiliates and new sales leader development in several markets as our leaders begin integrating Prysm iO into their
businesses and continue to build upon our leading anti-aging Tru Face® brand. We are focused on partnering with our sales force on leveraging the proprietary nutritional health biomarker tracking from Prysm iO to expand the channel as we prepare to
drive customer subscriptions for our wellness products. While these initiatives will take time to develop, we remain confident that they will increase sales leader engagement and expand our global reach over time to drive the next phase of growth for
Nu Skin.”
Nu Skin Enterprises Reports First Quarter 2026 Financial Results
page 2
Q1 2026 Year-over-year Operating Results
Revenue
$320.6 million compared to $364.5 million
• +1.1% FX impact or
$3.9 million
Gross Margin
66.9% or 67.9% excluding certain charges compared to 67.8%
• Nu Skin business was
76.9% compared to 76.7%
Selling Expenses
34.3% compared to 32.5%
• Nu Skin business was
40.5% compared to 38.7%
G&A Expenses
30.7% or 29.9% excluding certain charges compared to 31.1% or 28.9% excluding certain charges
Impairment Expenses
$1.8 million impairment compared to $25.1 million impairment
Operating Margin
1.3% or 3.6% excluding certain charges compared to (2.7)% or 6.4% excluding impairment and other charges
Interest Expense
$4.3 million compared to $3.3 million
Other Income (Expense)
$2.8 million compared to $(28.4) million
• Prior year reflects
$28.1 million unrealized loss on investment
Income Tax Rate
29.4% compared to 20.1%
EPS
$0.04 or $0.14 excluding certain charges compared to $2.14 or $0.23 excluding one-time gain from Mavely sale and other charges
Stockholder Value
Dividend Payments
$2.9 million
Stock Repurchases
$5.0 million
• $137.3 million
remaining in authorization
Q2 and Full-year 2026 Outlook
Q2 2026 Revenue
$330 to $360 million; (15)% to (7)%
• Approximately 0% FX
impact
Q2 2026 EPS
$0.15 to $0.25
2026 Revenue
$1.35 to $1.50 billion; (9)% to 1%
• Approximately (1)% FX
impact
2026 EPS
$0.70 to $1.10 or $0.80 to $1.20 excluding certain charges
“In addition to delivering on revenue and adjusted earnings, we returned $8 million to
shareholders in the form of dividends and share repurchases,” said Chelsea Lantz, interim chief financial officer. “We were also able to refinance our debt, extending our liquidity as we invest in growth
initiatives and navigate market volatility while executing on our strategy. We are maintaining our annual guidance for 2026 on an adjusted basis. For the second quarter, we project
revenue between $330 million and $360 million, with earnings per share in the range of $0.15 to $0.25.”
Nu Skin Enterprises Reports First Quarter 2026 Financial Results
page 3
Conference Call
The Nu Skin Enterprises management team will host a conference call with the investment community today at 5 p.m. (ET). Those wishing to access the
webcast, as well as the financial information presented during the call, can visit the Investor Relations page on the company’s website at ir.nuskin.com. A replay of the webcast will be available on the same page through May 21, 2026.
About Nu Skin Enterprises Inc.
Nu Skin Enterprises Inc. (NYSE: NUS) is an intelligent beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by more than 40 years of scientific research, the company’s products
help people look, feel and live their best with our newly introduced Prysm iO intelligent wellness platform, an award-winning line of beauty device systems and trusted brands in personal care and wellness products. Rhyz is the strategic investment
arm of Nu Skin Enterprises, formed in 2018 consisting of synergistic consumer, technology and manufacturing companies focused on innovation within the beauty, wellness and lifestyle categories.
Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the
company’s current expectations and beliefs. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws and include, but are not limited to, statements of management’s
expectations regarding the company’s performance, growth, initiatives, plans, areas of focus, sales force and customers, shareholder value, Prysm launch and its timing and potential benefits to the business, and emerging market expansion and its
timing; projections regarding revenue, expenses, margins, tax rates, earnings per share, foreign currency fluctuations, uses of cash, financial position and other financial items; statements of belief; and statements of assumptions underlying any
of the foregoing. In some cases, you can identify these statements by forward-looking words such as “believe,” “expect,” “become,” “continue,” “project,” “outlook,” “guidance,” “focus,” “expand,” “will,” “would,” “could,” “may,” “might,” the
negative of these words and other similar words.
Nu Skin Enterprises Reports First Quarter 2026 Financial Results
page 4
The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially
from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:
•
any failure of current or planned initiatives or products to generate interest among the company’s sales force and customers and generate sponsoring and selling activities on a
sustained basis;
•
risk that direct selling laws and regulations in any of the company’s markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner
that results in negative changes to the company’s business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, increased scrutiny of sales force actions,
imposition of fines, or any other adverse actions or events;
•
economic conditions and events globally;
•
the company’s future tax-planning initiatives, any prospective or retrospective increases in duties or tariffs on the company’s products imported into the company’s markets, and
any adverse results of tax audits or unfavorable changes to tax laws in the company’s various markets;
•
competitive pressures in the company’s markets;
•
risk that epidemics or other crises, as well as any related disruptions, could negatively impact our business;
•
adverse publicity related to the company’s business, products, industry or any legal actions or complaints by the company’s sales force or others;
•
political, legal, tax and regulatory uncertainties, including trade policies, associated with operating in Mainland China and other international markets;
•
uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China on our business
operations and results;
•
risk of foreign-currency fluctuations and the currency translation impact on the company’s business associated with these fluctuations;
•
uncertainties regarding the future financial performance of the businesses the company has acquired;
•
risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and increased risk of
inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies; and
•
regulatory risks associated with the company’s products, which could require the company to modify its claims or inhibit its ability to import or continue selling a product in a
market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements.
The company’s financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated
risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company’s beliefs as of the date that such information was first provided, and the company assumes no duty
to update the forward-looking statements contained in this release to reflect any change except as required by law.
Non-GAAP Financial Measures:
Constant-currency revenue change is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company’s performance. It is calculated by
translating the current period’s revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing that amount to the prior-year period’s revenue. The company believes that constant-currency revenue
change is useful to investors, lenders and analysts because such information enables them to gauge the impact of foreign-currency fluctuations on the company’s revenue from period to period.
Nu Skin Enterprises Reports First Quarter 2026 Financial Results
page 5
Earnings per share, gross margin, general and administrative expenses, and operating margin, each excluding inventory write-off charges, impairment
expense, the gain from the Mavely sale, unrealized investment loss, and/or other charges, also are non-GAAP financial measures.
•
Inventory write-off charges, impairment expense, and unrealized investment loss are not part of the ongoing operations of our underlying business; and
•
the gain from the Mavely sale, and the other charges incurred in connection with this sale and other corporate actions, are not part of our ongoing operations.
The company believes that these non-GAAP financial measures are useful to investors, lenders and analysts because removing the impact of these items
facilitates period-to-period comparisons of the company’s performance. Please see the reconciliations of these items to our earnings per share, gross margin, operating margin, income tax rate and revenue growth rate calculated under GAAP, below.
The following table sets forth revenue for the three-month periods ended March 31, 2026, and 2025 for each of our reportable segments (U.S. dollars in thousands):
Three Months Ended
March 31,
Change
Constant-
Currency
Change
Nu Skin
2026
2025
Americas
$
57,818
$
69,058
(16.3
)%
(12.6
)%
Southeast Asia/Pacific
45,474
52,172
(12.8
)%
(16.6
)%
Mainland China
45,148
47,775
(5.5
)%
(10.0
)%
Japan
39,739
42,765
(7.1
)%
(4.3
)%
Europe & Africa
31,218
33,021
(5.5
)%
(14.8
)%
Hong Kong/Taiwan
27,457
28,447
(3.5
)%
(5.9
)%
South Korea
25,329
32,515
(22.1
)%
(21.4
)%
Nu Skin Other
(234
)
529
(144.2
)%
(144.4
)%
Total Nu Skin
271,949
306,282
(11.2
)%
(12.5
)%
Rhyz
Manufacturing
44,925
55,290
(18.7
)%
(18.7
)%
Rhyz Other
3,734
2,918
28.0
%
28.0
%
Total Rhyz
48,659
58,208
(16.4
)%
(16.4
)%
Total
$
320,608
$
364,490
(12.0
)%
(13.1
)%
Nu Skin Enterprises Reports First Quarter 2026 Financial Results
page 6
The following table provides information concerning the number of Customers, Paid Affiliates and Sales Leaders in our core Nu Skin business for the three-month periods
ended March 31, 2026 and 2025:
Three Months Ended
March 31,
2026
2025
Change
Customers
Americas
186,448
227,514
(18
)%
Southeast Asia/Pacific
67,461
74,584
(10
)%
Mainland China
104,721
122,474
(14
)%
Japan
102,392
107,742
(5
)%
Europe & Africa
115,343
130,154
(11
)%
Hong Kong/Taiwan
35,899
42,523
(16
)%
South Korea
57,271
71,721
(20
)%
Total Customers
669,535
776,712
(14
)%
Paid Affiliates
Americas
27,039
26,936
0
%
Southeast Asia/Pacific
18,163
22,296
(19
)%
Mainland China
18,064
19,859
(9
)%
Japan
19,224
21,073
(9
)%
Europe & Africa
13,607
15,184
(10
)%
Hong Kong/Taiwan
9,541
9,622
(1
)%
South Korea
15,212
16,548
(8
)%
Total Paid Affiliates
120,850
131,518
(8
)%
Sales Leaders
Americas
4,930
6,174
(20
)%
Southeast Asia/Pacific
3,769
4,542
(17
)%
Mainland China
5,489
6,214
(12
)%
Japan
5,943
6,210
(4
)%
Europe & Africa
2,314
2,839
(19
)%
Hong Kong/Taiwan
2,123
2,207
(4
)%
South Korea
2,347
2,850
(18
)%
Total Sales Leaders
26,915
31,036
(13
)%
●
“Customers” are persons who have purchased directly from the Company during the three months ended as of the date indicated. Our Customer numbers include members of our sales force who made such a
purchase, including Paid Affiliates and those who qualify as Sales Leaders, but they do not include consumers who purchase directly from members of our sales force.
●
“Paid Affiliates” are any Brand Affiliates, as well as members of our sales force in Mainland China, who earned sales compensation during the three-month period. In all of our markets besides
Mainland China, we refer to members of our independent sales force as “Brand Affiliates” because their primary role is to promote our brand and products through their personal social networks.
●
“Sales Leaders” are the three-month average of our monthly Brand Affiliates, as well as sales employees and independent marketers in Mainland China, who achieved certain qualification requirements
as of the end of each month of the quarter.
Nu Skin Enterprises Reports First Quarter 2026 Financial Results
page 7
NU SKIN ENTERPRISES, INC.
Consolidated Statements of Income (Unaudited)
(U.S. dollars in thousands, except per share amounts)
Three Months Ended
March 31,
2026
2025
Revenue
$
320,608
$
364,490
Cost of sales
106,145
117,529
Gross profit
214,463
246,961
Operating expenses:
Selling expenses
110,054
118,546
General and administrative expenses
98,544
113,204
Impairment expenses
1,839
25,114
Total operating expenses
210,437
256,864
Operating income (loss)
4,026
(9,903
)
Interest expense
4,250
3,283
Gain on sale of business
-
176,162
Other income (expense), net
2,823
(28,375
)
Income before provision for income taxes
2,599
134,601
Provision for income taxes
763
27,086
Net income
$
1,836
$
107,515
Net income per share:
Basic
$
0.04
$
2.16
Diluted
$
0.04
$
2.14
Weighted-average common shares outstanding (000s):
Basic
48,202
49,764
Diluted
49,422
50,328
Nu Skin Enterprises Reports First Quarter 2026 Financial Results
page 8
NU SKIN ENTERPRISES, INC.
Consolidated Balance Sheets (Unaudited)
(U.S. dollars in thousands)
March 31,
December 31,
2026
2025
ASSETS
Current assets:
Cash and cash equivalents
$
198,654
$
238,630
Current investments
1,751
1,211
Accounts receivable, net
45,013
39,544
Inventories, net
178,600
178,643
Prepaid expenses and other
98,870
89,670
Total current assets
522,888
547,698
Property and equipment, net
381,610
377,168
Operating lease right-of-use assets
70,350
74,021
Goodwill
83,625
83,625
Other intangible assets, net
39,290
42,614
Other assets
279,035
280,187
Total assets
1,376,798
1,405,313
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable
$
28,815
$
26,183
Accrued expenses
208,182
217,551
Current portion of long-term debt
20,000
20,000
Total current liabilities
256,997
263,734
Operating lease liabilities
54,017
57,640
Long-term debt
203,593
204,187
Other liabilities
68,104
74,512
Total liabilities
582,711
600,073
Commitments and contingencies
Stockholders’ equity:
Class A common stock – 500 million shares authorized, $0.001 par value, 90.6 million shares issued
91
91
Additional paid-in capital
613,890
635,994
Treasury stock, at cost – 42.0 million and 42.4 million shares
(1,560,799
)
(1,575,059
)
Accumulated other comprehensive loss
(118,377
)
(116,105
)
Retained earnings
1,859,282
1,860,319
Total stockholders’ equity
794,087
805,240
Total liabilities and stockholders’ equity
$
1,376,798
$
1,405,313
Nu Skin Enterprises Reports First Quarter 2026 Financial Results
page 9
NU SKIN ENTERPRISES, INC.
Reconciliation of Gross Margin Excluding Impact of Inventory Write-off to GAAP Gross Margin
(in thousands, except for per share amounts)
Three months ended
March 31,
2026
2025
Gross profit
$
214,463
$
246,961
Impact of inventory write-off
3,116
-
Adjusted gross profit
$
217,579
$
246,961
Gross margin
66.9
%
67.8
%
Gross margin, excluding inventory write-off impact
67.9
%
67.8
%
Revenue
$
320,608
$
364,490
NU SKIN ENTERPRISES, INC.
Reconciliation of General and Administrative Expenses Excluding Certain Charges to GAAP General and Administrative Expenses
(in thousands, except for per share amounts)
Three months ended
March 31,
2026
2025
General and administrative expenses
$
98,544
$
113,204
Impact of other charges(1)
(2,643
)
(7,966
)
Adjusted general and administrative expenses
$
95,901
$
105,238
General and administrative expenses as a percentage of revenue
30.7
%
31.1
%
General and administrative expenses as a percentage of revenue, excluding certain charges
29.9
%
28.9
%
Revenue
$
320,608
$
364,490
(1) Other charges for the first quarter of 2026 consist of $1.0
million related to the wind down of the separate BeautyBio business and $1.6 million of other employee severance charges. Other charges for the first quarter of 2025 consist of expenses incurred in connection with the Mavely sale, including $2.7
million of transaction bonuses for certain employees and $5.2 million of equity compensation as a result of the vesting of the Mavely profits interest units.
Nu Skin Enterprises Reports First Quarter 2026 Financial Results
page 10
NU SKIN ENTERPRISES, INC.
Reconciliation of Operating Margin Excluding Certain Charges to GAAP Operating Margin
(in thousands, except for per share amounts)
Three months ended
March 31,
2026
2025
Operating income (loss)
$
4,026
$
(9,903
)
Impact of inventory write-off
3,116
-
Impact of other charges(1)
2,643
7,966
Impact of impairment
1,839
25,114
Adjusted operating income
$
11,624
$
23,177
Operating margin
1.3
%
(2.7
)%
Operating margin, excluding certain charges
3.6
%
6.4
%
Revenue
$
320,608
$
364,490
NU SKIN ENTERPRISES, INC.
Reconciliation of Earnings Per Share Excluding Impact of Certain Charges to GAAP Earnings Per Share
(in thousands, except for per share amounts)
Three months ended
March 31,
2026
2025
Net income
$
1,836
$
107,515
Impact of inventory write-off
Inventory write-off
3,116
-
Tax impact
(1,065
)
-
Impact of other charges:
Other charges(1)
2,643
7,966
Tax impact
(903
)
(725
)
Impact of impairment expense:
Impairment
1,839
25,114
Tax impact
(629
)
(5,433
)
Impact of Mavely sale
Gain from Mavely sale
-
(176,162
)
Tax impact
-
31,104
Impact of unrealized investment loss
Unrealized investment loss
-
28,077
Tax impact
-
(6,074
)
Adjusted net income
$
6,837
$
11,382
Diluted earnings per share
$
0.04
$
2.14
Diluted earnings per share, excluding restructuring impact
$
0.14
$
0.23
Weighted-average common shares outstanding (000)
49,422
50,328
Nu Skin Enterprises Reports First Quarter 2026 Financial Results
page 11
NU SKIN ENTERPRISES, INC.
Reconciliation of Earnings Per Share Excluding Impact of Certain Charges to GAAP Earnings Per Share
Year ended December 31,
2026 -
Low end
2026 -
High end
Earnings Per Share
$
0.70
$
1.10
Impact of inventory write-off
Inventory write-off
0.06
0.06
Tax impact
(0.02
)
(0.02
)
Impact of other charges
Other charges(1)
0.05
0.05
Tax impact
(0.02
)
(0.02
)
Impact impairment expense:
Impairment
0.04
0.04
Tax impact
(0.01
)
(0.01
)
Adjusted EPS
$
0.80
$
1.20
# # #
CONTACTS:
Media: media@nuskin.com, (801) 345-6397
Investors: investorrelations@nuskin.com, (801) 345-3577
GRAPHIC
GRAPHIC
Filename: image01.jpg · Sequence: 6
Binary file (3722 bytes)
Download image01.jpg
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 8
v3.26.1
Document and Entity Information
May 07, 2026
Cover [Abstract]
Document Type
8-K
Amendment Flag
false
Document Period End Date
May 07, 2026
Entity File Number
001-12421
Entity Registrant Name
NU SKIN ENTERPRISES, INC.
Entity Central Index Key
0001021561
Entity Incorporation, State or Country Code
DE
Entity Tax Identification Number
87-0565309
Entity Address, Address Line One
75 West Center Street
Entity Address, City or Town
Provo
Entity Address, State or Province
UT
Entity Address, Postal Zip Code
84601
City Area Code
801
Local Phone Number
345-1000
Title of 12(b) Security
Class A Common Stock, $.001 par value
Trading Symbol
NUS
Security Exchange Name
NYSE
Entity Emerging Growth Company
false
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration